What is the recommended management for a child suspected of pertussis, including antibiotics, supportive care, hospitalization criteria, infection control, prophylaxis, and immunization?

Management of Pertussis in Children

Antibiotic Treatment

Azithromycin is the first-line antibiotic for treating pertussis in children of all ages, with age-specific dosing: 10 mg/kg (maximum 500 mg) on day 1, followed by 5 mg/kg (maximum 250 mg) daily on days 2-5 for children ≥6 months, and 10 mg/kg daily for 5 days for infants <6 months. 1, 2

Age-Specific Antibiotic Recommendations

• For infants <1 month: Azithromycin is the preferred agent due to significantly lower risk of infantile hypertrophic pyloric stenosis (IHPS) compared to erythromycin, which is strongly associated with IHPS in this age group and should be avoided. 1, 2

• For infants 1-5 months: Azithromycin or clarithromycin are first-line options based on in vitro effectiveness, safety profile, and convenient dosing schedules. 1, 2

• For children ≥6 months and adults: Azithromycin 500 mg on day 1, then 250 mg daily on days 2-5 for adults; pediatric dosing as above. 1, 2

• Alternative for macrolide contraindications: Trimethoprim-sulfamethoxazole (TMP-SMZ) for patients >2 months who cannot tolerate macrolides. 1, 2

Timing and Clinical Effectiveness

• Start antibiotics immediately upon clinical suspicion without waiting for culture confirmation, as early treatment during the catarrhal phase (first 2 weeks) rapidly clears B. pertussis from the nasopharynx, decreases coughing paroxysms by approximately 50%, and reduces complications. 2, 3

• After 3 weeks of cough (paroxysmal phase), antibiotics have limited clinical benefit for symptom reduction but remain critical for preventing transmission, as 80-90% of untreated patients spontaneously clear the organism within 3-4 weeks. 2

• Macrolide therapy eradicates B. pertussis from the nasopharynx regardless of when treatment begins, making it essential for infection control even in late-stage disease. 3

Supportive Care

• Do not use β-agonists, antihistamines, corticosteroids, or pertussis immunoglobulin, as these therapies have no proven benefit in controlling coughing paroxysms or improving clinical outcomes. 2, 3

• Monitor for common complications including weight loss, sleep disturbance, post-tussive vomiting, and pressure-related effects (pneumothorax, epistaxis, subconjunctival hemorrhage, rib fracture). 3

• Watch for infectious complications such as primary or secondary bacterial pneumonia and otitis media, as well as serious neurological complications including seizures and hypoxic encephalopathy, which require immediate evaluation. 3

Hospitalization Criteria

• Infants <12 months, especially those <4 months, have the highest risk of severe and fatal pertussis complications including apnea, pneumonia, seizures, and death, warranting strong consideration for hospitalization. 2, 4

• Infants <1 month receiving macrolides should be monitored for IHPS and other serious adverse events. 1

• The risk of severe disease requiring hospitalization is significantly lower in older children and adolescents (1-2% hospitalization rate), though they remain important sources of transmission. 3

Infection Control and Isolation

• Isolate patients at home and away from work/school for 5 days after starting antibiotics to prevent transmission, as pertussis is highly contagious with secondary attack rates exceeding 80% among susceptible household contacts. 2, 3

• If antibiotics cannot be administered, isolation must continue for 21 days after cough onset. 3

• In healthcare settings, place confirmed pertussis patients in private rooms or cohort with other pertussis patients after the first 5 days of antimicrobial treatment. 5

• Wear a surgical mask when within 3 feet of a patient with confirmed or suspected pertussis, in addition to standard precautions. 5, 4

Postexposure Prophylaxis

• Administer macrolide prophylaxis to all household and close contacts within 21 days of exposure, regardless of age and vaccination status, using the same antibiotic regimens and dosing as for treatment. 1, 2, 4

• Priority groups for prophylaxis include: all household contacts, infants <12 months (especially <4 months), pregnant women in the third trimester, and healthcare workers with known exposure. 1, 4

• Prophylaxis aims to eradicate B. pertussis from the nasopharynx of infected persons (symptomatic or asymptomatic) and prevent secondary transmission to high-risk individuals. 4

• Asymptomatic contacts receiving prophylaxis can continue normal activities including work; routine testing is not recommended—focus on clinical monitoring. 4

Immunization Considerations

• Vaccination does not confer complete or lifelong immunity—breakthrough infections occur due to waning immunity beginning 5-10 years post-vaccination, making previously protected individuals susceptible again. 2, 3

• Continue routine DTaP vaccination schedule for siblings and household contacts who are not up-to-date, as vaccine immunity wanes and neither vaccination nor natural disease provides lifelong protection. 2, 3

• No recommendation exists for administering additional pertussis vaccine doses to children with well-documented pertussis disease (culture-positive or epidemiologically linked to culture-positive case). 5

• Children with documented pertussis should receive DT vaccine for remaining doses to ensure diphtheria and tetanus protection. 3

Diagnostic Confirmation

• Obtain nasopharyngeal aspirate or Dacron swab for culture and/or PCR testing to confirm B. pertussis, as culture isolation is the only certain diagnostic method. 2

• Suspect pertussis when cough lasts ≥2 weeks with paroxysms, post-tussive vomiting, and/or inspiratory whooping, even in fully vaccinated individuals who may present with atypical symptoms. 3

• Perform diagnostic testing on hospitalized patients with suspected pertussis to allow earliest possible downgrading of infection-control precautions. 5

Common Pitfalls to Avoid

• Do not dismiss pertussis based solely on vaccination status—vaccinated children can develop breakthrough infections with atypical presentations, often lacking the characteristic "whoop." 3

• Do not delay testing or treatment while waiting for classic symptoms—early intervention reduces transmission and may shorten disease course by 50%. 2, 3

• Recognize that azithromycin is recommended by CDC for infants <6 months despite lack of FDA licensure for this age group, as the risk of severe pertussis outweighs potential medication risks. 2

• Avoid erythromycin in infants <6 months due to strong association with IHPS; azithromycin has a significantly lower risk profile. 1, 2

• Remember that antibiotic prophylaxis does not provide long-term protection—vaccination remains the most important preventive strategy. 4